<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1003" relname="span">iSGLT2s are a new class of oral hypoglycaemic drugs</segment>
<segment id="3" parent="2" relname="elaboration">that block glucose reabsorption at the renal level ,</segment>
<segment id="4" parent="1004" relname="joint">thus promoting urine glucose and sodium excretion</segment>
<segment id="5" parent="1004" relname="joint">and reducing plasma glucose levels .</segment>
<segment id="6" parent="1005" relname="joint">In the present study , we have focused on the effects of empagliflozin on oxidative stress in the leukocytes of T2D subjects , and on inflammatory parameters .</segment>
<segment id="7" parent="1008" relname="span">In addition to a reduction in body weight and an improved metabolic profile</segment>
<segment id="8" parent="1009" relname="span">—</segment>
<segment id="9" parent="8" relname="elaboration">characterized by reduced plasma glucose and HbA1c levels —</segment>
<segment id="10" parent="1010" relname="span">we observed a reduction in mitochondrial superoxide production in diabetic patients</segment>
<segment id="11" parent="10" relname="circumstance">after treatment with the iSGLT2 empagliflozin , together with increased antioxidant defenses .</segment>
<segment id="12" parent="1012" relname="span">Moreover , reduced proinflammatory markers and increased anti-inflammatory parameters were maintained after 24 weeks of treatment with empagliflozin .</segment>
<segment id="13" parent="1013" relname="same_unit">Besides their glucose-lowering effect ,</segment>
<segment id="14" parent="1014" relname="span">iSGLT2s produce changes in the lipid profile</segment>
<segment id="15" parent="14" relname="elaboration">that should also be highlighted .</segment>
<segment id="16" parent="1016" relname="preparation">Empagliflozin treatment is correlated with increased total cholesterol</segment>
<segment id="17" parent="1017" relname="preparation">due to slight increases in HDL-c and LDL-c ,</segment>
<segment id="18" parent="1019" relname="joint">as we have observed ,</segment>
<segment id="19" parent="1019" relname="joint">and reported in other studies .</segment>
<segment id="20" parent="1021" relname="span">However , there is a well-documented cardiovascular protection</segment>
<segment id="21" parent="20" relname="elaboration">exerted by iSGLT2s ,</segment>
<segment id="22" parent="1021" relname="elaboration">which endows these drugs with clinical potential .</segment>
<segment id="23" parent="1023" relname="span">This has been reflected by several studies , such as the EMPA-REG OUTCOME study</segment>
<segment id="24" parent="23" relname="elaboration">in which a reduction of 38 % in cardiovascular mortality was evident in the empagliflozin vs. placebo group .</segment>
<segment id="25" parent="1025" relname="same_unit">However , neither the reduction in HbA1c</segment>
<segment id="26" parent="1027" relname="span">observed in the study</segment>
<segment id="27" parent="26" relname="elaboration">( 0.60 % over 12 weeks )</segment>
<segment id="28" parent="1030" relname="span">nor the reduction in SBP</segment>
<segment id="29" parent="28" relname="elaboration">( up to 5 mmHg )</segment>
<segment id="30" parent="1029" relname="same_unit">are sufficient</segment>
<segment id="31" parent="1029" relname="purpose">to explain the reported protection against cardiovascular mortality .</segment>
<segment id="32" parent="1032" relname="span">Interestingly , as little as 24 weeks of treatment with iSGLT2 is sufficient</segment>
<segment id="33" parent="32" relname="purpose">to witness their beneficial effects on HbA1c , body weight , blood pressure and , most importantly , on the cardiovascular system .</segment>
<segment id="34" parent="1035" relname="span">As an example , the reduction in hospitalization rates for heart failure in the group</segment>
<segment id="35" parent="34" relname="elaboration">treated with empagliflozin in the EMPA-REG OUTCOME study</segment>
<segment id="36" parent="1034" relname="same_unit">was already significant at this time point .</segment>
<segment id="37" parent="1017" relname="joint">A recent study demonstrated an improved arterial stiffness after 6 weeks of treatment with empagliflozin in T2D patients ,</segment>
<segment id="38" parent="1017" relname="joint">and hs-CRP was shown to be one of the main significant determinants for this improvement .</segment>
<segment id="39" parent="1039" relname="span">Nevertheless ,</segment>
<segment id="40" parent="1041" relname="concession">despite the available evidence ,</segment>
<segment id="41" parent="1041" relname="span">the molecular mechanisms</segment>
<segment id="42" parent="1042" relname="span">underlying the cardiovascular protection attributable to iSGLT2 treatment are still unknown ,</segment>
<segment id="43" parent="42" relname="concession">though amelioration of oxidative stress has been hypothesized to be a potential contributor .</segment>
<segment id="44" parent="1044" relname="span">Because cardiac tissue possesses low antioxidant defenses ,</segment>
<segment id="45" parent="44" relname="elaboration">increasing the expression or activity of antioxidant enzymes could be a mechanism of cardiac protection under high risk situations such as T2D .</segment>
<segment id="46" parent="1046" relname="same_unit">Oxidative stress occurs</segment>
<segment id="47" parent="1048" relname="circumstance">when the production of pro-oxidant species overcomes the intrinsic antioxidant defense system of the cell ,</segment>
<segment id="48" parent="1048" relname="joint">thus triggering damage to lipids , proteins and DNA ,</segment>
<segment id="49" parent="1048" relname="joint">and eventually compromising cellular and tissue function .</segment>
<segment id="50" parent="1050" relname="span">Exploring the role of SGLT2 inhibition in the prevention or reduction of oxidative stress conditions</segment>
<segment id="51" parent="50" relname="elaboration">has been the subject of several studies over the last decade .</segment>
<segment id="52" parent="1052" relname="span">However , to date , most of the studies</segment>
<segment id="53" parent="1053" relname="span">evaluating the effect of iSGLT2 on oxidative stress</segment>
<segment id="54" parent="53" relname="elaboration">have been performed in animal models .</segment>
<segment id="55" parent="1056" relname="attribution">Our data demonstrate</segment>
<segment id="56" parent="1056" relname="joint">that T2D patients receiving iSGLT2 treatment undergo a reduction in mitochondrial superoxide production in parallel to an increase in glutathione content ,</segment>
<segment id="57" parent="1056" relname="joint">and markedly so after 24 weeks of treatment .</segment>
<segment id="58" parent="1058" relname="span">This is accompanied by increased expression of the antioxidant enzymes GSR and CAT .</segment>
<segment id="59" parent="58" relname="elaboration">However , no changes in plasma protein carbonyl content were observed with empagliflozin treatment at these time-points .</segment>
<segment id="60" parent="1060" relname="contrast">Whether this could be due to the small sample size</segment>
<segment id="61" parent="1060" relname="contrast">or would require long-term empagliflozin treatment needs to be addressed in future research .</segment>
<segment id="62" parent="1062" relname="span">Our findings are in accordance with previous studies in rat models of T2D ,</segment>
<segment id="63" parent="62" relname="elaboration">in which increased antioxidant enzyme content and activity in renal tissues has been reported .</segment>
<segment id="64" parent="1063" relname="span">Furthermore , iSGLT2 treatment in diabetic mice has been shown</segment>
<segment id="65" parent="1065" relname="span">to induce antioxidant gene expression</segment>
<segment id="66" parent="65" relname="elaboration">( manganese-dependent superoxide dismutase and CAT )</segment>
<segment id="67" parent="1064" relname="same_unit">in adipose tissue and muscle .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1005" relname="background"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="multinuc" parent="1003" relname="elaboration"/>
<group id="1005" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1005" relname="joint"/>
<group id="1008" type="span" parent="1007" relname="span"/>
<group id="1009" type="span" parent="7" relname="elaboration"/>
<group id="1010" type="span" parent="1008" relname="elaboration"/>
<group id="1012" type="span" parent="1005" relname="joint"/>
<group id="1013" type="multinuc" parent="12" relname="elaboration"/>
<group id="1014" type="span" parent="1013" relname="same_unit"/>
<group id="1015" type="span" parent="1005" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1017" type="multinuc" parent="1016" relname="span"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="multinuc" parent="1020" relname="concession"/>
<group id="1020" type="span" parent="1018" relname="span"/>
<group id="1021" type="span" parent="1020" relname="span"/>
<group id="1023" type="span" parent="1017" relname="joint"/>
<group id="1025" type="multinuc" parent="1017" relname="joint"/>
<group id="1026" type="multinuc" parent="1025" relname="same_unit"/>
<group id="1027" type="span" parent="1026" relname="same_unit"/>
<group id="1028" type="span" parent="1026" relname="same_unit"/>
<group id="1029" type="multinuc" parent="1028" relname="span"/>
<group id="1030" type="span" parent="1029" relname="same_unit"/>
<group id="1032" type="span" parent="1017" relname="joint"/>
<group id="1034" type="multinuc" parent="1017" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1039" type="span" parent="1017" relname="joint"/>
<group id="1040" type="span" parent="39" relname="concession"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="span" parent="41" relname="elaboration"/>
<group id="1044" type="span" parent="1017" relname="joint"/>
<group id="1046" type="multinuc" parent="1017" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="same_unit"/>
<group id="1048" type="multinuc" parent="1047" relname="span"/>
<group id="1050" type="span" parent="1017" relname="joint"/>
<group id="1052" type="span" parent="1017" relname="joint"/>
<group id="1053" type="span" parent="52" relname="elaboration"/>
<group id="1054" type="multinuc" parent="1017" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="sequence"/>
<group id="1056" type="multinuc" parent="1055" relname="span"/>
<group id="1057" type="multinuc" parent="1054" relname="sequence"/>
<group id="1058" type="span" parent="1057" relname="joint"/>
<group id="1060" type="multinuc" parent="1057" relname="joint"/>
<group id="1062" type="span" parent="1057" relname="joint"/>
<group id="1063" type="span" parent="1057" relname="joint"/>
<group id="1064" type="multinuc" parent="64" relname="purpose"/>
<group id="1065" type="span" parent="1064" relname="same_unit"/>
	</body>
</rst>
